# QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer

> **NCT01834235** · PHASE1,PHASE2 · TERMINATED · sponsor: **Precision Biologics, Inc** · enrollment: 81 (actual)

## Conditions studied

- Pancreatic Cancer, Adult

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** nab-paclitaxel
- **DRUG:** NPC-1C

## Key facts

- **NCT ID:** NCT01834235
- **Lead sponsor:** Precision Biologics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-04
- **Primary completion:** 2017-03-13
- **Final completion:** 2019-12
- **Target enrollment:** 81 (ACTUAL)
- **Why stopped:** DSMB terminated the trial for futility.
- **Last updated:** 2025-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01834235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01834235, "QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01834235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*